Aeolus Pharmaceuticals (AOLS) stock price, revenue, and financials

Aeolus Pharmaceuticals market cap is $410.6 k, and annual revenue was $2.08 m in FY 2016

$410.6 K

AOLS Mkt cap, 23-Sept-2020

$13 K

Aeolus Pharmaceuticals Revenue Q3, 2017
Aeolus Pharmaceuticals Net income (Q3, 2017)-949 K
Aeolus Pharmaceuticals EBIT (Q3, 2017)-949 K
Aeolus Pharmaceuticals Cash, 30-Jun-2017403 K

Aeolus Pharmaceuticals Income Statement

Aeolus Pharmaceuticals Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

518.0k281.0k869.0k1.5m94.0k3.2m

Accounts Receivable

1.7m882.0k370.0k1.6m1.6m750.0k

Prepaid Expenses

63.0k61.0k39.0k46.0k45.0k

Current Assets

2.3m1.2m1.9m3.5m1.7m4.1m

Total Assets

2.3m1.3m2.0m3.6m1.8m4.2m

Accounts Payable

2.1m2.3m579.0k1.6m1.6m972.0k

Short-term debt

727.0k

Current Liabilities

2.1m2.3m1.3m2.0m2.6m972.0k

Total Debt

727.0k

Total Liabilities

25.5m21.6m1.3m2.0m2.6m972.0k

Common Stock

605.0k627.0k1.3m1.4m1.4m

Preferred Stock

5.0k5.0k5.0k5.0k5.0k

Additional Paid-in Capital

158.5m159.7m183.3m184.2m184.4m191.9m

Retained Earnings

(182.4m)(180.7m)(183.9m)(184.0m)(186.6m)(190.2m)

Total Equity

(23.3m)(20.3m)705.0k1.6m(845.0k)3.2m

Debt to Equity Ratio

-0.9 x

Debt to Assets Ratio

0.4 x

Financial Leverage

-0.1 x-0.1 x2.8 x2.3 x-2.1 x1.3 x

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

883.0k1.2m390.0k207.0k2.0k1.9m2.7m534.0k520.0k1.3m447.0k248.0k416.0k5.4m4.5m3.8m1.9m981.0k403.0k

Accounts Receivable

466.0k1.5m2.5m2.4m1.6m1.6m343.0k1.1m1.8m2.7m1.8m1.8m656.0k871.0k1.4m742.0k544.0k603.0k313.0k

Prepaid Expenses

76.0k56.0k210.0k55.0k54.0k92.0k51.0k38.0k96.0k70.0k65.0k110.0k73.0k66.0k156.0k317.0k178.0k149.0k46.0k

Current Assets

1.4m2.7m3.1m2.6m1.6m4.6m4.1m2.7m3.9m4.9m2.7m2.2m1.2m6.4m6.2m4.8m2.6m1.7m762.0k

Total Assets

1.5m2.8m3.1m2.7m1.6m4.7m4.1m2.8m3.9m4.9m2.8m2.2m1.2m6.4m6.3m4.9m2.6m1.8m794.0k

Accounts Payable

555.0k3.1m3.4m3.2m3.1m2.0m2.0m1.4m2.4m2.4m1.3m1.8m1.5m796.0k1.0m661.0k514.0k638.0k587.0k

Short-term debt

Current Liabilities

555.0k3.1m3.4m3.2m3.1m3.1m3.0m2.5m3.9m3.3m1.7m1.8m1.5m796.0k1.2m688.0k514.0k638.0k587.0k

Long-term debt

273.0k273.0k

Total Debt

273.0k273.0k

Total Liabilities

22.8m22.9m19.8m16.0m17.9m3.1m3.0m2.5m3.9m3.3m1.7m1.8m1.5m796.0k1.2m688.0k514.0k638.0k587.0k

Common Stock

605.0k605.0k622.0k627.0k627.0k1.3m1.3m1.3m1.3m1.3m1.4m1.4m1.4m1.5m1.5m1.5m1.5m1.5m1.5m

Preferred Stock

5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k

Additional Paid-in Capital

158.3m158.7m159.4m159.7m159.8m182.7m183.0m183.5m183.7m183.8m184.4m184.5m184.5m191.8m191.8m191.8m191.9m191.9m191.9m

Retained Earnings

(180.3m)(179.4m)(176.7m)(173.6m)(176.7m)(182.5m)(183.3m)(184.6m)(185.1m)(183.5m)(184.7m)(185.4m)(186.2m)(187.7m)(188.3m)(189.2m)(191.3m)(192.3m)(193.3m)

Total Equity

(21.4m)(20.1m)(16.7m)(13.3m)(16.2m)1.6m1.1m278.0k37.0k1.6m1.1m434.0k(289.0k)5.6m5.0m4.2m2.1m1.1m207.0k

Debt to Equity Ratio

0 x0.1 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

-0.1 x-0.1 x-0.2 x-0.2 x-0.1 x2.9 x3.7 x9.9 x105.1 x3 x2.6 x5.2 x-4.2 x1.1 x1.2 x1.2 x1.2 x1.6 x3.8 x

Aeolus Pharmaceuticals Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

299.0k1.7m(3.2m)(80.0k)(2.6m)(3.6m)

Depreciation and Amortization

5.0k7.0k6.0k

Accounts Receivable

1.7m(795.0k)411.0k(1.2m)(26.0k)835.0k

Accounts Payable

1.2m128.0k(1.6m)973.0k46.0k(626.0k)

Cash From Operating Activities

(3.1m)(879.0k)(3.0m)323.0k(2.4m)(3.1m)

Purchases of PP&E

Cash From Investing Activities

Short-term Borrowings

Cash From Financing Activities

1.3m642.0k3.6m325.0k1.0m6.2m

Net Change in Cash

(1.8m)(237.0k)588.0k648.0k(1.4m)3.1m

Aeolus Pharmaceuticals Ratios

USDQ3, 2011

Financial Leverage

-0.1 x